Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bright Minds Biosciences Inc

38.89
-3.7500-8.80%
Post-market: 38.970.0850+0.22%18:17 EDT
Volume:29.77K
Turnover:1.20M
Market Cap:275.64M
PE:-36.80
High:42.44
Open:42.44
Low:38.56
Close:42.64
52wk High:79.02
52wk Low:0.9400
Shares:7.09M
Float Shares:3.00M
Volume Ratio:0.76
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0565
EPS(LYR):-0.4812
ROE:-30.79%
ROA:-18.31%
PB:7.31
PE(LYR):-80.81

Loading ...

Bright Minds Biosciences to Present at Upcoming Conferences

GlobeNewswire
·
Aug 25

Bright Minds Biosciences (DRUG) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Jul 01

Bright Minds Biosciences (DRUG) Receives a Buy from Chardan Capital

TIPRANKS
·
May 21

Bright Minds announces speakers for Absence epilepsy R&D Day

TIPRANKS
·
May 20

Bright Minds Biosciences Says BMB-101 Eliminated Drop Attacks in Mouse Model of Epilepsy

MT Newswires Live
·
May 13

TD Cowen Initiates Coverage on Bright Minds Biosciences With Buy Rating

MT Newswires Live
·
May 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 13

Bright Minds initiated with a Buy at TD Cowen

TIPRANKS
·
May 13

Bright Minds Biosciences’ BMB-101: A Promising Anti-Seizure Drug with Billion-Dollar Market Potential

TIPRANKS
·
May 13

Chardan Initiates Bright Minds Biosciences at Buy With $80 Price Target

MT Newswires Live
·
May 07

Chardan Capital Initiates a Buy Rating on Bright Minds Biosciences (DRUG)

TIPRANKS
·
May 07

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

GlobeNewswire
·
Apr 28

Psychedelic: Clearmind completes clinical site initiations for AUD trial

TipRanks
·
Apr 25

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks
·
Mar 22

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
Mar 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 11

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 07

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

GlobeNewswire
·
Mar 06

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

GlobeNewswire
·
Mar 04